Form 4 for EW Edwards Lifesciences
Accepted 2026-04-02 17:13:52 ET · period of report 2026-04-02 · accession 0001225208-26-004249 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2026-04-02 17:13 | 2026-04-02 | EW | BOBO DONALD E JR | CVP, Strategy, Corp Development | M - OptEx | $59.26 | +22.7K | 43.9K | +107% | +$1.34M |
| DMT | 2026-04-02 17:13 | 2026-04-02 | EW | BOBO DONALD E JR | CVP, Strategy, Corp Development | S - Sale+OE | $80.16 | -22.7K | 21.3K | -52% | -$1.82M |
| DT | 2026-04-02 17:13 | 2026-04-02 | EW | BOBO DONALD E JR | CVP, Strategy, Corp Development | M - OptEx | $0.00 | -22.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-02 | M | A | 22,680 | $59.26 | 43,946.25 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. |
| 2 | Common | Common Stock | 2026-04-02 | S | D | 4,676 | $80.59 | 39,270.25 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. (F2) This transaction was executed in multiple trades at prices ranging from $80.510 to $80.660. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 3 | Common | Common Stock | 2026-04-02 | S | D | 18,004 | $80.05 | 21,266.25 | D | — | — | (F1) The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025. (F3) This transaction was executed in multiple trades at prices ranging from $79.490 to $80.435. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide, uponrequest by the SEC staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
| 4 | Derivative | Employee Stock Option (Right to Acquire) | 2026-04-02 | M | D | 22,680 | $0.00 | 0 | D | $59.26 · 2019-06-08 to 2026-05-07 | 22,680 Common Stock |